Features of the course of AA-amyloidosis in rheumatoid arthritis against the background of COVID-19 infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Rheumatoid arthritis (Ra) is currently one of the most common causes of AA amyloidosis; and the renal damage is associated with the severity of systemic inflammation. severe chronic infections can also lead to the development and progression of aa amyloidosis, and acute infections can worsen the course of aa amyloidosis. The evaluation of the features of the course of aa amyloidosis against the background of a new coronavirus infection is of undoubted interest. The article presents authors’ own clinical observation of the development of nephrotic syndrome against the background of SARS-CoV-2 in a patient with seropositive Ra and morphologically confirmed AA-amyloidosis.

Full Text

Restricted Access

About the authors

Elena V. Voloshinova

Saratov State Medical University named after V.I. Razumovsky

Email: voloshinovaelena@mail.ru
Cand. Sci. (Med.), Associate Professor at the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

Natalya M. Nikitina

Saratov State Medical University named after V.I. Razumovsky

Email: nikina02@yandex.ru
Dr. Sci. (Med.), Professor at the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

Natalya D. Smirnova

Saratov State Medical University named after V.I. Razumovsky

Email: syrrax@yandex.ru
Resident at the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

Ekaterina V. Egorova

Saratov State Medical University named after V.I. Razumovsky

Email: kapustik@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of General Medicine Saratov, Russia

References

  1. Merlini G., Bellotti V., Molecular Mechanisms of Amyloidosis. N. Engl. J. Med. 2003; 349: 583-596. doi: 10.1056/NEJMra023144.
  2. Лысенко Л.В. (Козловская), Рамеев В.В., Моисеев С.В., и соавт. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин. фармакология и терапия, 2020;1:13-24. Doi: 10.32756/ 0869-5490-2020-1-13-24.
  3. Мухин Н.А. Клинические проблемы амилоидоза почек. Клин. мед. 1983; 61:7-12
  4. Ahlmen M., Ahlmen J., Svalander C., Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin. Rheumatol. 1987; 6: 27-38. doi: 10.1007/BF02200997.
  5. Чеботарева Н.В., Гуляев С.В., Андросова Т.В. и соавт. Хроническая болезнь почек у больных ревматоидным артритом: частота, факторы риска, варианты поражения почек. Терапевтический архив. 2019;91(5):129-133.doi: 10.26442/00403660.2019.05.000255
  6. Муравьев Ю.В., Раденска-Лоповок С.Г., Алексеева А.В., с соавт. Необычное течение АА-амилоидоза у больной ревматоидным артритом. Научно- практическая ревматология. 2009;2:73-75
  7. Козловская Л.В., Варшавский В.А., Чегаева Т.В. и соавт. Амилоидоз: современный взгляд на проблему. Практическая нефрология. 1998;2:16-23
  8. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69(4): 631-637. doi: 10.1136/ard.2009.123919.
  9. Kuroda T., Tanabe N., Kobayashi D., et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis // Rheumatol. Int. 2012;32(10):3155-3162. doi: 10.1007/s00296-011-2148-8.
  10. Муркамилов И.Т., Айтбаев К.А., Кудайбергенова И.О., Фомин В.В., Юсупов Ф.А. Ревматоидный артрит и поражения почек: современный взгляд на проблему. The scientific heritage. 2021;58:29-37. doi: 10.24412/9215-0365-2021-58-2-29-37
  11. Fernández-Nebro A., Tomero E., OrtizSantamaria V., et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am. J. Med. 2005;118(5):552-556. doi: 10.1016/j.amjmed.2005.01.028.
  12. Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy // Arthritis Rheum. 2003;48(7):2019-2024. doi: 10.1002/art.11163.
  13. Fiter J., Nolla J.M., Gomez Vaquero C., Valverde J. Treatment of amyloidosis secondary to rheumatoid arthritis with methotrexate. Med. Clin. (Barc). 2000;114(11):439. doi: 10.1016/s0025-7753(00)71323-6.
  14. Trefler J., Matyska-Piekarska E., Wagner T., KŁacki J. Amyloidosis-life threatening complication in rheumatoid arthritis patients. 2007;60(9-10): 457-461.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download